This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Allogene Therapeutics (ALLO)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
ALLOPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Ocuphire (OCUP) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Ocuphire (OCUP) is expected to provide updates on the clinical development of its lead retinal product candidate, APX3330, to treat diabetic retinopathy, in fourth-quarter 2023 earnings release.
VTRSNegative Net Change CGEMPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Xenon (XENE) Q4 Earnings Top Estimates, Pipeline in Focus
by Zacks Equity Research
Xenon (XENE) reports mixed fourth-quarter 2023 financial results, wherein earnings beat estimates but revenues missed the same. Its development programs for XEN1101 in epilepsy and MDD are progressing well.
ACETPositive Net Change ADMAPositive Net Change XENEPositive Net Change AKROPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Pacira (PCRX) Q4 Earnings Match, Exparel Sales Drive Revenues
by Zacks Equity Research
Pacira (PCRX) reports fourth-quarter 2023 results, wherein earnings match and revenues beat estimates, driven by strong Exparel sales.
ACETPositive Net Change PCRXPositive Net Change ADMAPositive Net Change AKROPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Catalyst (CPRX) Q4 Earnings & Sales Beat Estimates, Stock Up
by Zacks Equity Research
Catalyst (CPRX) reports encouraging fourth-quarter results, driven by Firdapse and Fycompa sales. The stock gains in the pre-market session.
ACETPositive Net Change CPRXPositive Net Change PBYIPositive Net Change ADMAPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
AXT (AXTI)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
AXTIPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Editas (EDIT) Q4 Earnings & Revenues Top Estimates, Stock Up
by Zacks Equity Research
Editas (EDIT) reports better-than-expected fourth-quarter 2023 results as both earnings and revenues beat estimates, driven by collaboration revenues received from Vertex. The stock gains 25%.
VRTXNegative Net Change ACETPositive Net Change EDITPositive Net Change AKROPositive Net Change
biotechnology biotechs cell-therapy crispr earnings gene-editing gene-therapy medical pharmaceuticals
2 Top-Ranked Crypto Stocks to Buy as Bitcoin Rockets Higher
by Tirthankar Chakraborty
Thanks to Bitcoin's recent epic run, stocks such as Nvidia (NVDA) and Coinbase Global (COIN) are poised to benefit.
NVDAPositive Net Change SQPositive Net Change MARAPositive Net Change COINPositive Net Change
biotechnology bitcoin cryptocurrency
After Golden Cross, Lancaster Colony (LANC)'s Technical Outlook is Bright
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Viatris' (VTRS) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Viatris (VTRS) reports lower-than-expected fourth-quarter financial results, as both earnings and sales miss estimates. Stock declines in pre-market.
ACETPositive Net Change PBYIPositive Net Change ADMAPositive Net Change VTRSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Denali's (DNLI) Q4 Earnings Miss, Pipeline in Focus, Stock Up
by Zacks Equity Research
Denali (DNLI) reports lower than expected fourth-quarter financial results. The stock, however, rises 38% on news of funding raised by the company, which is expected to strengthen its cash position.
SNYPositive Net Change BIIBPositive Net Change PBYIPositive Net Change DNLIPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Beyond the "Mag 7": 3 Risk-On Market Forces
by Andrew Rocco
The biggest bear argument over the past year has been the slim leadership in the market, namely concentrated in mega-cap tech stocks like the "Mag 7." However, dig deeper, and you will discover that the market is broadening quickly.
TNegative Net Change NVDAPositive Net Change IWMPositive Net Change VKTXPositive Net Change METAPositive Net Change BITBPositive Net Change
biotechnology biotechs bitcoin investing magnificent-7
Wynn Resorts (WYNN) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
WYNNPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Fate Therapeutics (FATE) Q4 Earnings Beat, Revenues Fall Y/Y
by Zacks Equity Research
Fate Therapeutics (FATE) reports encouraging fourth-quarter results as loss narrows year over year due to lower operating expenses.
ACETPositive Net Change PBYIPositive Net Change FATEPositive Net Change ADMAPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Journey Medical (DERM) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
When Journey Medical (DERM) reports fourth-quarter 2023 results, investors will likely focus on the top and bottom-line numbers.
CLDXPositive Net Change ESPRPositive Net Change DERMPositive Net Change APLSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Should You Buy Tenaya Therapeutics, Inc. (TNYA) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
TNYANegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Eton Pharma (ETON) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Eton Pharma's (ETON) revenues in the fourth quarter of 2023 are expected to have been driven by the sales of its marketed products.
SRPTPositive Net Change CGENPositive Net Change ETONPositive Net Change ARQTPositive Net Change
biotechnology biotechs medical pharmaceuticals
Bausch (BHC) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Bausch (BHC) fourth-quarter earnings and sales beat their respective estimates. The guidance for 2024 looks encouraging.
PBYIPositive Net Change ADMAPositive Net Change EDITPositive Net Change BHCNegative Net Change
biotechnology biotechs earnings pharmaceuticals
Sanmina (SANM) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
SANMPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Why Apellis (APLS) Might Surprise This Earnings Season
by Zacks Equity Research
Apellis (APLS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
APLSPositive Net Change
biotechnology biotechs medical
Intra-Cellular (ITCI) Q4 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Intra-Cellular (ITCI) reports mixed fourth-quarter 2023 results despite Caplyta sales rising year over year on the back of increasing prescription trends.
ACETPositive Net Change PBYIPositive Net Change ADMAPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Biotech Stock Roundup: MRNA's Q4 Results, RAPT Down on Study Results & Other Updates
by Zacks Equity Research
Earnings from Moderna (MRNA) and pipeline update from RAPT are in focus in the biotech sector.
REGNNegative Net Change MRNAPositive Net Change SRPTPositive Net Change IOVAPositive Net Change RAPTPositive Net Change
biotechnology biotechs pharmaceuticals
CRISPR (CRSP) Q4 Earnings Top on Collaboration Revenues, Stock Up
by Zacks Equity Research
CRISPR (CRSP) gains on encouraging fourth-quarter 2023 results, beating both earnings and revenue estimates on the back of collaboration revenues received from Vertex.
VRTXNegative Net Change PBYIPositive Net Change ADMAPositive Net Change CRSPPositive Net Change
biotechnology biotechs cell-therapy crispr dna-sequencing earnings gene-editing gene-therapy medical pharmaceuticals
Biotech/Drug Stocks Q4 Earnings Due Feb 22: MRNA, BHC, NTLA, BMRN & More
by Ekta Bagri
Let us take a look at what's in store for biotech/drug stocks MRNA, BHC, NTLA, BMRN and ITCI, which are scheduled to report on Feb 22.
BMRNPositive Net Change MRNAPositive Net Change NTLAPositive Net Change BHCNegative Net Change
biotechnology biotechs earnings pharmaceuticals
Bristol Myers' (BMY) Krazati sNDA for CRC Gets Priority Review
by Zacks Equity Research
Bristol Myers (BMY) announces FDA's acceptance of the sNDA seeking approval for the Krazati/Erbitux combo therapy to treat CRC patients. A final decision is expected on Jun 21, 2024.
BMYNegative Net Change ACETPositive Net Change PBYIPositive Net Change ADMAPositive Net Change
biotechnology biotechs medical pharmaceuticals